We and others have demonstrated that the phosphatidylinositol-3-kinase (PI3K)/PTEN/AKT/mT0R pathway is activated in over 60% of endometrial cancers by mutations in the PTEN (30-50%), PIK3CA (20-40%), PIK3R1 (20%) and AKT1 (-2%) genes. Further, we and others have shown that the RAS/RAF pathway is activated by KRAS mutations in -20% of endometrial cancers. In contrast to other cancer types, none of these mutations are mutually exclusive and two or more thus frequently occur in the same endometrial tumor. We and others have also recently demonstrated that KRAS mutations predict a lack of response to PISK pathway-targeted therapies in cancer cells and vice versa. Thus, in this application, we will test the hypotheses in vitro and in vivo in endometrial cancer that: 1. PISK pathway-targeted drugs will be selectively active in tumors with mutations in the PISK pathway in the absence of KRAS mutations, 2. Specific aberrations in the PISK pathway will determine the response to targeting different nodes in the PISK pathway, 3. Aberrations in the RAS/RAF pathway in the absence of PISK pathway mutations will render tumors responsive to RAS/RAF-pathway targeted drugs (e.g. MEK inhibitors), and 4. Cells with coordinate mutations in both the PISK and RAS/RAF pathways will be resistant to PISK pathway inhibitors and MEK inhibitors alone but sensitive to concurrent targeting of both pathways.
Our specific aims are thus:
Aim 1 : To determine effects of mutations in the PISK and RAS/RAF pathways on downstream signaling events and clinical correlates in endometrial cancer.
Aim 2 : To determine whether specific aberrations in the PISK and RAS/RAF pathways predict effects of targeting specific nodes in the PISK and RAS/RAF pathways.
Aim 3 : To identify and validate predictive and pharmacodynamic markers of antitumor efficacy for PISK- and RAS/RAF-targeted therapies in endometrial cancer.
Aim 4 : To determine whether predictive and pharmacodynamic markers indicate responsiveness to the dual PISK/mTOR inhibitor GSK2126458A in a phase II clinical trial in advanced endometrial cancer.

Public Health Relevance

PISK and RAS/RAF pathway mutations occur in >65% of endometrial cancers. It is therefore likely that our studies of these two pathways as therapy targets in endometrial cancer will benefit a significant proportion of women with endometrial cancer when translated to the clinic. In addition, these mutations are seen frequently in a broad spectrum of tumor types including breast and colorectal cancers. Thus, the proposed studies of PISK and RAS/RAF pathway inhibition in endometrial cancer will likely also have broad applicability to other tumor types.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098258-09
Application #
8521101
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
9
Fiscal Year
2013
Total Cost
$184,929
Indirect Cost
$71,351
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yates, Melinda S; Coletta, Adriana M; Zhang, Qian et al. (2018) Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prev Res (Phila) 11:477-490
Yan, F; Thall, P F; Lu, K H et al. (2018) Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. Ann Oncol 29:694-699
Gao, Chao; Wang, Yingmei; Broaddus, Russell et al. (2018) Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget 9:5492-5508
Pan, Haitao; Liu, Suyu; Miao, Danmin et al. (2018) Sample size determination for mediation analysis of longitudinal data. BMC Med Res Methodol 18:32
Suidan, Rudy S; Sun, Charlotte C; Cantor, Scott B et al. (2018) Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol 132:52-58
Chu, Yiyi; Yuan, Ying (2018) A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clin Trials 15:149-158
Gharpure, Kshipra M; Pradeep, Sunila; Sans, Marta et al. (2018) FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9:2923
Crumley, Suzanne; Kurnit, Katherine; Hudgens, Courtney et al. (2018) Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Mod Pathol :
Mitamura, T; Pradeep, S; McGuire, M et al. (2018) Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene 37:722-731
Aslan, Ozlem; Cremona, Mattia; Morgan, Clare et al. (2018) Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro. BMC Cancer 18:168

Showing the most recent 10 out of 578 publications